Planview Reports Record Q2 and H1 2023, Continues Momentum Amid Challenging Economic Landscape
20.7.2023 18:18:00 EEST | Business Wire | Press release
Planview, the leading platform for digital connected work from portfolio planning to delivery, announced today record annual recurring revenue (ARR) and bookings in Q2, continuing strong momentum and growth in 2023. ACV Bookings for Q2 and the first half of the year were at a record high approaching 30% growth year-over-year (YoY), driven by both new customer additions and customer expansions across financial services, automotive, and healthcare. At the close of H1 2023, Planview is outpacing its forecasts on several key measures, including bookings, retention, and ARR this year. These results are driven by significant demand from customers who require data-driven insights to effectively prioritize initiatives, allocate capital and utilize resources across digital transformation efforts.
“The macroenvironment continues to pose challenges for digital transformation efforts in companies around the world. Organizations are faced with inflation, changing customer expectations, and more conservative budgets,” said Razat Gaurav, CEO at Planview. “At the same time, they must continue to drive forward transformation initiatives to adapt and achieve key business outcomes. Planview’s connected solution is uniquely positioned to give leaders and organizations the data-driven alignment, transparency, and visibility to make critical prioritization decisions, enabling companies to increase productivity, improve time-to-market, and de-risk strategic bets.”
H1 2023 Highlights
- Strong ACV bookings growth for the first half of 2023, approaching 30% growth YoY
- Significant improvements to Retention through first half of 2023, +100bps improvement to Net Retention YoY
- Recurring Revenue grew 13% during the first half of 2023 YoY
- Added over 126 net new customers
- Grew total active users for University of Planview by 29% quarter-over-quarter
Strong New Logo and Customer Momentum
Planview’s outperformance and profitable growth has been driven by new customer wins and expansions. New and notable customers who partnered or significantly expanded their footprint with Planview include AT&T, Axcelis Technologies, Bausch + Lomb, Baylor Scott & White Health, CellCarta, ChristianaCare, Commonwealth Bank of Australia, Corewell Health, Ecopetrol Group, Foodstuffs, Ford Motor Company, Inland Empire Health Plan, LandSure Systems, Mitsubishi UFJ Financial Group, New York Life Insurance Company, Omnicell, OneSavings Bank, PagoNxt, Pladis Global, Schaeffler Group, Schwab, Sherwin-Williams, Sun Life Financial, Transport for NSW, Tronox Holdings, Vanguard Group, Vonage, and Voya.
Industry Leadership & Product Innovation
Key milestones that support continued customer success and the company's strong growth:
- Showcased new Generative AI based assistant at the Reuters Momentum AI Summit.
- Released the landmark 2023 Project to Product State of the Industry Report, which revealed that 40% of Digital Innovation work is being wasted today.
- Recognized for the second consecutive year as a leader in the 2023 Gartner® Magic Quadrant™ for Strategic Portfolio Management. The company was positioned furthest for Completeness of Vision.
- Expanded its global footprint with growing teams in North America, EMEA, Israel and India, with a focus on Artificial Intelligence (AI), Data Science, R&D, Premium Support, Managed Services, InfoSec, and Partners/Strategic Alliances.
- Increased its global partner ecosystem with the additions of UiPath and NTT Data, focused on delivering Value Stream Management capabilities.
- Dramatically expanded its partnership with AWS, including achievement of AWS ISV Accelerate Program membership and the launch of five Planview solutions in the AWS Marketplace.
- Increased in monthly active users by 15% YoY for leading products.
Planview is continuing to invest heavily in product innovation, customer success and go-to-market, building a foundation for continued customer satisfaction and growth in 2023 and beyond.
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720450990/en/
Contact information
Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom